Why do semaglutide and Mounjaro cause nausea, and what helps?
Why semaglutide and tirzepatide make many people feel sick, and how often. Plus what labels and guidelines, including India's, say helps.
Written for India. Reading from the US? US versionComing soon
GLP-1 medicines slow your stomach and act on sickness centres in the brainstem. In US label trials, 11% to 44% felt sick (nausea), vs 4% to 16% on placebo, mostly as doses rose. Guidelines describe small, slow, low-fat meals. Vomiting that won't stop can dehydrate you and harm the kidneys.
- GLP-1 medicines are prescription-only in India. A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.15 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.16
- This post reports what labels and published guidance say. It is not a plan for changing your dose or diet.
- Nausea is one of several side effects. The full list, with the serious ones, is in Guide 5, Side effects and risks.
Key takeaways
- GLP-1 medicines cause nausea in two ways: they slow how fast the stomach empties, and they act on brainstem areas that trigger sickness.1
- In the US Mounjaro label, nausea rose from 12% at 5 mg to 18% at 15 mg, against 4% on placebo.5
- Nausea on semaglutide 2.4 mg peaked around week 20 in the STEP trials, and a typical bout of nausea lasted about 8 days.7
- India's ESI 2025 obesity guideline lists small, frequent meals, fewer high-fat meals, and buttermilk, kokum juice, fennel seeds or ginger candy for nausea.9
- Vomiting or diarrhoea that won't stop can cause dehydration, and the Wegovy label reports kidney injury after this, sometimes needing dialysis.2
On this page
- Why do semaglutide and tirzepatide (Mounjaro) make you feel sick?
- How common is nausea on each medicine and dose?
- When does the nausea start, and how long does it last?
- Does feeling sick mean the medicine is working?
- What do guidelines say helps with nausea?
- Which Indian foods and drinks do the sources mention?
- What can a doctor change if the nausea doesn't settle?
- When does vomiting put your kidneys at risk?
- Which symptoms need urgent help?
- Questions people ask
- How we researched this
Why do semaglutide and tirzepatide (Mounjaro) make you feel sick?
These medicines slow down your stomach and gut, and they reach brainstem areas that set off sickness. A 2026 review says both routes probably play a part.1
The first route is in the gut. GLP‑1 medicines slow the rate at which food leaves the stomach (gastric emptying), and they slow the small intestine too.1 The US labels for semaglutide and tirzepatide both state that the medicine delays stomach emptying.2,5
The second route is in the brain. A small brainstem area, the area postrema, has no full blood-brain barrier, so medicines in the blood reach it. The review calls it a typical trigger zone for medicine-induced nausea, and says GLP‑1 medicines can act on it directly.1
Signals also travel from the gut to the brainstem along the vagus nerve, the main nerve linking the two.1 The same review says slower emptying, nausea and eating less are separate effects, not one effect seen three ways.1
Our guide on what GLP‑1 medicines do explains the hormone behind this. Our GLP‑1 full form answer covers the name.
How common is nausea on each medicine and dose?
The EU labels for Ozempic and Mounjaro list nausea as very common (more than 1 in 10 people). It rises with the dose, and weight-loss trials report more.18,3,5,8
Across these labels, 11% to 44% felt sick on the medicine, against 4% to 16% on placebo.2,4,5
The table gives the share of people who reported nausea or vomiting at least once in each label's placebo-controlled trials. These are US labels, not Indian ones, because we could not find Indian pack inserts online. Each row comes from different trials and people, so rows can't be compared head to head.
| Medicine (US label) | Felt sick (nausea) | Vomited | On placebo |
|---|---|---|---|
| Ozempicsemaglutide injection, type 2 diabetes | 0.5 mg: 16% 1 mg: 20% | 0.5 mg: 5% 1 mg: 9% | Nausea 6%, vomiting 2%3 |
| Rybelsussemaglutide tablets, type 2 diabetes | 7 mg: 11% 14 mg: 20% | 7 mg: 6% 14 mg: 8% | Nausea 6%, vomiting 3%4 |
| Wegovysemaglutide injection, weight | 2.4 mg: 44% | 2.4 mg: 24% | Nausea 16%, vomiting 6%2 |
| Mounjarotirzepatide injection, type 2 diabetes | 5 mg: 12% 10 mg: 15% 15 mg: 18% | 5 mg: 5% 10 mg: 5% 15 mg: 9% | Nausea 4%, vomiting 2%5 |
| Tirzepatide for weightUS Zepbound label | 5 mg: 25% 10 mg: 29% 15 mg: 28% | 5 mg: 8% 10 mg: 11% 15 mg: 13% | Nausea 8%, vomiting 2%6 |
Share of people reporting each effect at least once, rounded. Sources: US labels for Ozempic (May 2026), Rybelsus (Jan 2026), Wegovy (Jun 2026), Mounjaro and Zepbound (Aug 2026). Checked 5 Oct 2026.
In the US, tirzepatide for weight is sold as Zepbound. In India, Mounjaro is approved for both type 2 diabetes and weight management.17 Our answer on whether Mounjaro is available in India covers the brands. Our post on Mounjaro side effects covers the rest of the label.
A Spanish expert consensus says weight trials see slightly more stomach effects, probably because their doses are higher.8
The US Wegovy label now includes a 7.2 mg dose. In its trials, 39% felt sick on 7.2 mg, vs 35% on 2.4 mg and 13% on placebo.2 We found no Indian approval for 7.2 mg.
Indian trials point the same way
One 24-week trial included 314 Indians with type 2 diabetes. Stomach side effects hit 43% on a generic semaglutide and 47% on Ozempic, mostly mild or moderate.13
Another 24-week trial included 282 Indian adults with obesity. About 63% in each group had a side effect, mostly mild stomach symptoms, and nobody stopped because of one.14 Both compared a generic with Novo Nordisk's brand, had no placebo group and were paid for by the generic's maker.13,14
When does the nausea start, and how long does it last?
The labels say most nausea, vomiting and diarrhoea happens while the dose is being stepped up. In the big semaglutide weight trials, each bout of nausea lasted about 8 days.3,5,7
- First weeksPer the Spanish consensus, nausea is more frequent in the first 4 to 5 weeks, when emptying is slowest.8
- Each dose stepThe Ozempic, Rybelsus and Mounjaro labels say most reports came during dose increases.3,4,5 In the STEP trials, the dose rose every 4 weeks from 0.25 mg and reached 2.4 mg at week 16.7
- Around week 20Nausea on semaglutide 2.4 mg peaked at about week 20, then fell. Nausea fell more than any other stomach effect.7
- LaterThe Mounjaro label says the stomach effects decreased over time. Its delay in stomach emptying is largest after the first dose and shrinks after that.5
In the STEP trials, the median bout of nausea lasted 8 days and a bout of vomiting 2 days.7 A 2025 US nutrition advisory says nausea often comes in the morning, or after long gaps without food.10
Some people stop the medicine because of it. On the US Wegovy label, 1.8% stopped because of nausea, vs 0.2% on placebo.2 On Mounjaro, 3% to 7% stopped for stomach effects, depending on dose, vs 0.4% on placebo.5
Our answer on how long Ozempic takes to work covers the dose steps.
Does feeling sick mean the medicine is working?
Not in the trials' numbers. In the STEP trials of semaglutide 2.4 mg, people lost about the same weight whether or not they had stomach side effects.7
Stomach side effects (including nausea) explained less than 1 percentage point of the extra weight lost vs placebo. The authors ran this analysis after the trials ended (post hoc), so they call it exploratory.7
The analysis pooled 3 STEP trials of semaglutide 2.4 mg. Without stomach side effects, people lost 9.6% to 17.1% of their weight on average, and with them 11.4% to 17.7%.7 Novo Nordisk ran the trials, and one author worked for the company.7
These are group averages, not a promise for one person. The same trials also show the cost: 4.3% stopped because of stomach side effects.7 The Spanish consensus also concluded that weight loss was largely independent of stomach effects.8
India's ESI 2025 guideline frames it for counselling. It says people should be told these effects are a sign that the drug has begun acting.9 Both can hold: nausea can show the medicine has started to act, while STEP found it did not drive the weight lost.7,9
Our post on how much weight people lose on Ozempic or Mounjaro gives the full trial results.
- Nausea is very common (more than 1 in 10 people) on the EU Ozempic and Mounjaro labels. On Wegovy 2.4 mg, 44% felt sick and 24% vomited, vs 16% and 6% on placebo. Severe stomach effects hit 4.1% vs 0.9%.18,2
- Pancreatitis and gallbladder problems. Warning signs include severe stomach pain that won't go away, or upper stomach pain with fever or yellow skin and eyes.2
- Dehydration can hurt the kidneys. Kidney injury has been reported, sometimes needing dialysis.2
- Not for severe gastroparesis. The Wegovy label does not recommend it for people whose stomach already empties very slowly.2
- Thyroid tumour warning. Semaglutide caused thyroid C-cell tumours in rodents; whether it does in people is unknown. The US label rules it out with a personal or family history of medullary thyroid cancer (MTC) or MEN 2; tell your doctor if this applies.2
- Not in pregnancy. The US Wegovy label says it may harm an unborn baby. Its patient guide says to stop it 2 months before a planned pregnancy.2
What do guidelines say helps with nausea?
The published advice centres on eating less at a time, eating slowly and choosing low-fat food. It comes from expert panels and advisories, not from trials of each tip.8,9,10
We compared India's ESI 2025 guideline, a 2023 Spanish expert consensus and a 2025 US nutrition advisory.8,9,10 Novo Nordisk paid for the Spanish consensus.8 Here is what they say, in their own terms.
- US advisory: avoid long gaps without food. It describes a cycle where skipping meals makes nausea worse. It suggests a small breakfast, then small meals every 3 to 4 hours, with fluids.10
- Spanish consensus: eat slowly, stop when full. Its patient list includes eating slowly, eating only when really hungry and stopping at the first feeling of fullness.8
- Spanish consensus: stay upright after eating. The same list says not to lie down after a meal and not to eat close to bedtime.8
- Spanish consensus: sip, and keep drinks apart from meals. It suggests clear drinks in small sips. If nausea or vomiting persists, it suggests drinking 30 to 60 minutes before or after meals rather than with them.8
For nausea itself, the Spanish consensus names crackers, apples, mint and ginger, and says to avoid strong smells.8 The US advisory names ginger or peppermint tea.10 Our guide Life on a GLP‑1 covers protein and meals more broadly.
Which Indian foods and drinks do the sources mention?
India's ESI 2025 obesity guideline names buttermilk, kokum juice, fennel seeds, cloves, ginger candy, liquorice and ice for nausea. It is the only guideline we found that names Indian foods.9
The Endocrine Society of India (ESI) published its updated obesity guideline in 2025. Its table on stomach side effects lists:9
- To ease nausea: ginger candy, liquorice (mulethi), cloves (laung) and fennel seeds (saunf).9
- Something cold: ice cubes or ice candy.9
- Drinks without fizz, such as buttermilk (chaas) or kokum juice, in small amounts.9
- Meals: small and frequent, and not high in carbohydrate, fat or fibre.9
The guideline gives these as practical tips. It cites no trial of them in people on GLP‑1 medicines, and we found none.9 The ESI authors declared no conflicts of interest.9
Fried and spicy food
The Spanish consensus suggests low-fat, bland food, cooked in an oven, on a griddle or by boiling. It also says to avoid spicy food, sweet meals and sauces that aren't home-cooked.8 That consensus was written in Spain, not for Indian kitchens, so the spice advice is theirs, not an Indian rule.
Festival fasts
A 2017 Indian paper looked at Navratri food at home and in restaurant thalis. It says many dishes are fried or oily, including sabudana, singhara and kuttu preparations. It preferred grilling, boiling or steaming.11
That paper was about diabetes, not GLP‑1 medicines.11 Still, fried dishes are the high-fat meals the ESI tips steer away from.9 Guide 8 covers fasting on a GLP‑1, including Ramadan.
A printable checklist on side effects, other medicines and follow-up. No sign-up.
What can a doctor change if the nausea doesn't settle?
Labels and expert papers describe slower dose steps, a lower dose for longer, or short-term anti-nausea medicine. These are a doctor's decisions.2,8,10
The Mounjaro label says its starting dose and 4-week steps are there to reduce stomach side effects.5 Rybelsus starts at 3 mg for 30 days, a dose the label says does not control blood sugar.4 Our answer on Rybelsus 3 mg explains that step.
The sources describe these options:
- Wait before the next step. The US Wegovy label says the next dose increase can wait 4 weeks if a dose isn't tolerated.2
- Step back. The Spanish consensus describes holding a step 2 to 4 weeks longer, or briefly going back a step.8
- A lower long-term dose. The same paper says some people may stay below the label's top dose.8
- A pause. It also describes stopping for a while until symptoms clear, then restarting.8
- Short-term anti-nausea medicine, which both papers mention.8,10 The US advisory notes that some of these medicines can worsen constipation.10 If one is still needed after a month on the full dose, the Spanish paper suggests a lower dose.8
The US advisory, in a passage on how fast to lose weight rather than on nausea, says some people may benefit from slower dose steps.10 India's ESI guideline says the same in 3 words: "up titrate slowly".9
When does vomiting put your kidneys at risk?
Vomiting or diarrhoea that goes on can drain your body's water (dehydration). The US Wegovy label reports kidney injury in people who became dehydrated this way.2
The label describes reports, after the medicine went on sale, of sudden kidney injury (acute kidney injury), some needing dialysis. Most came after nausea, vomiting or diarrhoea had led to dehydration.2 It asks doctors to check kidney function in these patients, especially when starting or raising the dose.2
In Wegovy's weight trials, 7 people on the medicine had kidney injury, vs 4 on placebo. That is 0.4 vs 0.2 cases per 100 patient-years.2 The risk was higher in people who already had kidney problems.2
The US advisory says this can happen with or without existing kidney disease.10 The label's patient guide says to drink fluids to lower the chance of dehydration. It says to tell your doctor right away about nausea, vomiting or diarrhoea that does not go away.2
Signs of dehydration, from the NHS:12
- feeling thirsty, with a dry mouth, lips and tongue
- dark yellow, strong-smelling pee, or peeing less often
- feeling dizzy, light-headed or tired, or a headache
- sunken eyes
The NHS says dehydration is more likely with diabetes, vomiting, diarrhoea or too long in the heat.12 If you feel sick, it suggests starting with small sips and avoiding caffeine and alcohol. It says a pharmacist can suggest an oral rehydration solution (ORS) to replace lost salts.12
The Navratri paper warns that going without water in hot weather can cause dehydration.11 Our answer on GLP‑1s and kidneys will cover kidney disease itself.
Which symptoms need urgent help?
Most stomach side effects in the STEP trials were mild or moderate. The NHS lists signs that need emergency help, and the Wegovy label lists others for your doctor.7,12,19,2
- Sudden, severe stomach pain that spreads to your back, or comes with a fast heartbeat or trouble breathing. The NHS lists these for acute pancreatitis.19
- Signs of dehydration with confusion, cold, pale or blotchy skin, fast breathing, or being very sleepy or hard to wake. The NHS says these can mean shock.12
- Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing. The Wegovy patient guide says to stop the medicine and get medical help right away.2
Upper stomach pain, fever, yellow skin or eyes, or pale, clay-coloured stools can be gallbladder problems; the Wegovy patient guide says to call your healthcare provider.2
Tell your doctor right away, says the US Wegovy patient guide, about:2
- severe stomach pain that won't go away, with or without vomiting (it says to stop the medicine too)2
- nausea, vomiting or diarrhoea that does not go away2
The NHS adds that dizziness on standing that doesn't pass, dark yellow pee or peeing less than normal needs an urgent doctor's appointment.12
Severe ongoing pain and gallbladder signs are covered in depth in our post on pancreatitis and gallbladder risks. Guide 5 has the full list of serious risks.
Questions people ask
Why do I feel sick in the morning on Ozempic or Mounjaro?
A 2025 US nutrition advisory says GLP-1 nausea often comes in the morning or after a long gap without food. It suggests a small breakfast, then small meals every 3 to 4 hours, with fluids.10
Will the nausea come back when my dose goes up?
It can. The Ozempic, Rybelsus and Mounjaro labels all say most nausea, vomiting and diarrhoea happened during dose increases. The Mounjaro label says these effects decreased over time.3,4,5
Is nausea worse on Mounjaro or Ozempic?
The labels can't settle it, because each label's numbers come from different trials and people. On its own label, 12% to 18% felt sick on Mounjaro, vs 4% on placebo. On Ozempic's label, it was 16% to 20%, vs 6%.3,5
Can you take an anti-nausea tablet with a GLP-1 medicine?
A doctor may prescribe one for a short time; both expert papers we read mention this. Some can worsen constipation. One paper suggests a lower GLP-1 dose if one is still needed after a month.8,10
Should you tell your surgeon you're on a GLP-1 medicine?
Yes, the labels ask for this. Because these medicines slow stomach emptying, food can stay in the stomach during anaesthesia. The US labels describe a small number of reports, after the medicines went on sale, of food entering the lungs (pulmonary aspiration).2,5
How we researched this
On 5 October 2026 we read the US labels for Ozempic, Rybelsus, Wegovy, Mounjaro and Zepbound. We copied each nausea and vomiting figure from their tables.
We also read the full text of the 2026 JCI review and the STEP tolerability analysis. We read the ESI 2025 guideline, the Spanish consensus, the US advisory and both Indian trials the same way.
We could not find Indian pack inserts, so all rates are from US labels. We used the EU labels only for their frequency words. One Indian trial gives nausea as a share of side-effect events, not of people, so we left it out.
We found no source naming dishes like samosas as triggers, so we name only foods the sources name. We left out anti-nausea medicine names and doses, which are a prescriber's choice.
Before you move on
- GLP‑1 nausea comes from a slower stomach and from the brainstem.
- Most of it comes during dose increases, and higher doses bring more of it.
- India's ESI guideline lists small meals, less fat, and chaas, kokum, saunf or ginger.
- Vomiting that won't stop needs your doctor right away; signs of shock mean 112.
More from the India blog
Ozempic side effects: which are common and which are serious?
Mounjaro side effects: what the trials and the label say
How much weight do people lose on Ozempic or Mounjaro? What the trials found
The monthly India update
An independent guide to GLP‑1 medicines. We don't sell medicines, take drug-company money or earn clinic commissions. Once a month: new brands, price changes, approvals and recalls. How we write
Sources
- Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (review). J Clin Invest. 2026;136(4):e194740. DOI
- Novo Nordisk. Wegovy (semaglutide) US prescribing information and Medication Guide, revised June 2026 (US label, not the Indian one). PDF
- Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information, revised May 2026 (US label, not the Indian one). PDF
- Novo Nordisk. Rybelsus (semaglutide) tablets, US prescribing information, revised January 2026 (US label, not the Indian one). PDF
- Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised August 2026 (US label, not the Indian one). PDF
- Eli Lilly. Zepbound (tirzepatide) US prescribing information, revised August 2026 (US-only brand; the weight-trial data for tirzepatide). PDF
- Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24:94–105. Uses Novo Nordisk's STEP trial data; one author a Novo Nordisk employee. DOI · PMID 34514682 · Full text
- Gorgojo-Martínez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus (Spain). J Clin Med. 2023;12(1):145. Funded by Novo Nordisk (paper's own declaration). DOI · PMID 36614945 · Full text
- Madhu SV, Kapoor N, Das S, Raizada N, Kalra S. ESI clinical practice guidelines for the evaluation and management of obesity in India: an update (2025), Table 6. Indian J Endocrinol Metab. 2025. Authors declared no conflicts of interest. DOI · PMID 40917319
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society. Am J Clin Nutr. 2025;122:344–67. Declared interests: 4 authors declare Novo Nordisk ties and 5 declare Eli Lilly ties, as advisers or speakers (paper's own declaration). DOI · PMID 40445127
- Gupta L, Khandelwal D, Singla R, Gupta P, Kalra S. Pragmatic dietary advice for diabetes during Navratris. Indian J Endocrinol Metab. 2017;21(1):231–7. About diabetes, not GLP-1 medicines. DOI · PMID 28217524
- NHS. Dehydration. Page last reviewed 1 May 2026 (UK emergency numbers on that page; in India, call 112). Link
- Ambika Gopalakrishnan U, et al. Semaglutide injection in Indian patients with type 2 diabetes mellitus: a randomised, phase III, active-controlled study. Diabetes Obes Metab. 2026. Funded by Sun Pharmaceutical Industries. DOI · PMID 42219226 · Full text
- Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in Indian adults with obesity: a phase III randomized non-inferiority trial. Metabolism Open. 2026;30:100460 (corrigendum PMID 42327013 corrects the randomisation wording only). Funded by Zydus Lifesciences. DOI · PMID 41953358
- Press Information Bureau (PIB Research). GLP-1 Drugs: Use, Risks, and Regulation. Government backgrounder, 1 April 2026. PDF
- CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism): 20–21 April 2023, item 1 (tirzepatide), and 13–14 February 2024, items 3–4 (semaglutide, Novo Nordisk). Committee minutes. April 2023 PDF · archived copy · February 2024 PDF · archived copy
- Indian Pharma Post (IPP Bureau). Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes. 24 March 2025. Link
- European Medicines Agency. Ozempic (semaglutide) and Mounjaro (tirzepatide) EU product information (summary of product characteristics and package leaflet), section 4.8 frequency tables. EU labels, used here only for the frequency band. Ozempic PDF · Mounjaro PDF
- NHS. Acute pancreatitis. Page last reviewed 11 March 2026 (UK emergency numbers on that page; in India, call 112). Link
Last checked 5 Oct 2026 · Next review due 5 Oct 2027 · Report an error
How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write